Similar Papers

Paper Title
Journal
Date
Author
Tumor board presentation of a woman with metastatic, hormone receptor‐positive, mismatch repair‐deficient endometrial cancer
Jennifer A Bennett ... Katherine C Kurnit
CA: A Cancer Journal for Clinicians | VOL. 72
Jennifer A Bennett, et. al.Jennifer A Bennett ... Katherine C Kurnit
25 Jan 2022
New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer
Rogerio C Lilenbaum
Journal of Thoracic Oncology | VOL. 3
Rogerio C LilenbaumRogerio C Lilenbaum
01 Jun 2008
Clinical outcomes of MSI-high (MSI-H) versus stable (MSS) endometrial carcinoma (EC) after front-line platinum chemotherapy and subsequent matched therapy.
Natalie Ngoi ... Kah Wieng Tham
Journal of Clinical Oncology | VOL. 38
Natalie Ngoi, et. al.Natalie Ngoi ... Kah Wieng Tham
20 May 2020
619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial
Shannon N Westin ... Andreia Cristina De Melo
International Journal of Gynecologic Cancer | VOL. 34
Shannon N Westin, et. al.Shannon N Westin ... Andreia Cristina De Melo
01 Mar 2024
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
276MO Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
C-T Wu ... L-N Chien
Annals of Oncology | VOL. 35
C-T Wu, et. al.C-T Wu ... L-N Chien
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.